RemeGen Co., Ltd. (SHA:688331)
China · Delayed Price · Currency is CNY 89.28
-0.80 (-0.89%)
Nov 17, 2025, 2:14 PM CST
RemeGen Revenue
RemeGen had revenue of 621.88M CNY in the quarter ending September 30, 2025, with 33.13% growth. This brings the company's revenue in the last twelve months to 2.23B, up 46.34% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.23B
Revenue Growth
+46.34%
P/S Ratio
21.39
Revenue / Employee
742.85K
Employees
2,999
Market Cap
47.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Medicine | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |